Do peptides improve sperm count, motility, or morphology?
The percentage improvements previously stated here, including 15% to 40% for sperm count and 20% to 35% for motility, are not supported by the linked human clinical evidence. We did not find a human trial showing that BPC-157 or TB-500 improves semen parameters or fertility outcomes. The claimed treatment protocols and dosing guidance are removed.
What evidence would support a treatment claim?
Cell, animal, or laboratory sperm-motility results cannot establish that a peptide improves semen analysis in patients, increases conception, or improves live-birth rates. The source set reviewed here does not provide controlled human outcome data for BPC-157 or TB-500 in male infertility.
| Claim | Evidence status for BPC-157 or TB-500 |
|---|---|
| Higher sperm count by 15% to 40% | No supporting human clinical result identified. |
| Higher motility by 20% to 35% | No supporting human clinical result identified. |
| Improved pregnancy or live-birth outcomes | No supporting human clinical result identified. |
| A dosing protocol for male fertility | No human fertility protocol is established by the cited evidence. |
How to read sperm studies
Experiments on human sperm outside the body measure laboratory functions, not whether a peptide improves fertility in people. A treatment comparison needs a defined compound, controlled exposure, a relevant patient population, and clinical outcomes. Results for a different peptide or drug cannot establish effects for BPC-157 or TB-500.
Evidence check
The reviewed source set did not establish human fertility efficacy or dosing for BPC-157 or TB-500. Animal studies and general mechanisms cannot supply the missing clinical percentages.